Parameter
| Biomarker | miR-375 (microrNA-375) | Full name | microRNA-375 | Molecular Type | Non-coding RNA (microRNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis and prognosis | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Serum (qPCR, digital PCR), tumor tissue (qPCR, in situ hybridization) | ||
| Pathobiological Mechanisms | As a tumor suppressor microRNA, the expression of miR-375 in gastric cancer tissues and serum is low, which inhibits tumor cell proliferation and induces apoptosis by targeting oncogenes such as YAP1 and AEG-1. Patients with low expression of Mir-375 have strong tumor invasion and short survival time | ||||
| Clinical Availability Status | Basic research/early clinical: the diagnostic sensitivity is about 70%, the specificity is about 85%, and it is in the clinical verification stage of small samples | ||||
| Notes and Dynamics | Serum miR-375 level is correlated with the degree of gastric mucosal atrophy and intestinal metaplasia, which can be used as a monitoring indicator for the progression of gastric precancerous lesions. Combined with gastroscopy, the detection rate of early gastric cancer can be improved | ||||